Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Adjuvant radiation therapy for high-grade gliomas

Helen A Shih, MD
Tracy Batchelor, MD, MPH
Section Editors
Jay S Loeffler, MD
Patrick Y Wen, MD
Deputy Editor
April F Eichler, MD, MPH


High-grade gliomas are malignant brain tumors that include the most common malignant primary brain tumor in adults, glioblastoma, as well as anaplastic astrocytoma and anaplastic oligodendroglioma. The diffuse gliomas are further subdivided according to isocitrate dehydrogenase (IDH) mutation status and the presence or absence of codeletion of chromosomes 1p and 19q [1]. (See "Classification and pathologic diagnosis of gliomas".)

Most high-grade gliomas are best managed with a combined modality approach, incorporating adjuvant postoperative radiation therapy (RT) and adjuvant chemotherapy following initial surgery. Postoperative RT is discussed in this topic.

Other patient management topics that are covered separately include:

The diagnostic approach to patients with suspected brain tumors (see "Overview of the clinical features and diagnosis of brain tumors in adults")

Initial surgical management of high-grade gliomas (see "Clinical manifestations and initial surgical approach to patients with high-grade gliomas")

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Sep 2017. | This topic last updated: Oct 06, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. WHO Classification of Tumours of the Central Nervous System, 4th ed, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), IARC, Lyon 2016.
  2. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980; 303:1323.
  3. Andersen AP. Postoperative irradiation of glioblastomas. Results in a randomized series. Acta Radiol Oncol Radiat Phys Biol 1978; 17:475.
  4. Walker MD, Alexander E Jr, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978; 49:333.
  5. Coffey RJ, Lunsford LD, Taylor FH. Survival after stereotactic biopsy of malignant gliomas. Neurosurgery 1988; 22:465.
  6. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979; 5:1725.
  7. Chang CH, Horton J, Schoenfeld D, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 1983; 52:997.
  8. Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr 1988; :279.
  9. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980; 30:907.
  10. Wallner KE, Galicich JH, Krol G, et al. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1989; 16:1405.
  11. Choucair AK, Levin VA, Gutin PH, et al. Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. J Neurosurg 1986; 65:654.
  12. Liang BC, Thornton AF Jr, Sandler HM, Greenberg HS. Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. J Neurosurg 1991; 75:559.
  13. Ten Haken RK, Thornton AF Jr, Sandler HM, et al. A quantitative assessment of the addition of MRI to CT-based, 3-D treatment planning of brain tumors. Radiother Oncol 1992; 25:121.
  14. Thornton AF Jr, Hegarty TJ, Ten Haken RK, et al. Three-dimensional treatment planning of astrocytomas: a dosimetric study of cerebral irradiation. Int J Radiat Oncol Biol Phys 1991; 20:1309.
  15. Glatstein E, Lichter AS, Fraass BA, et al. The imaging revolution and radiation oncology: use of CT, ultrasound, and NMR for localization, treatment planning and treatment delivery. Int J Radiat Oncol Biol Phys 1985; 11:299.
  16. Gross MW, Weber WA, Feldmann HJ, et al. The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas. Int J Radiat Oncol Biol Phys 1998; 41:989.
  17. Douglas JG, Stelzer KJ, Mankoff DA, et al. [F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys 2006; 64:886.
  18. Chang J, Thakur S, Perera G, et al. Image-fusion of MR spectroscopic images for treatment planning of gliomas. Med Phys 2006; 33:32.
  19. Narayana A, Yamada J, Berry S, et al. Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results. Int J Radiat Oncol Biol Phys 2006; 64:892.
  20. Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 2002; 20:1635.
  21. Paulino AC, Mai WY, Chintagumpala M, et al. Radiation-induced malignant gliomas: is there a role for reirradiation? Int J Radiat Oncol Biol Phys 2008; 71:1381.
  22. Shrieve DC, Alexander E 3rd, Black PM, et al. Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J Neurosurg 1999; 90:72.
  23. Prisco FE, Weltman E, de Hanriot RM, Brandt RA. Radiosurgical boost for primary high-grade gliomas. J Neurooncol 2002; 57:151.
  24. Masciopinto JE, Levin AB, Mehta MP, Rhode BS. Stereotactic radiosurgery for glioblastoma: a final report of 31 patients. J Neurosurg 1995; 82:530.
  25. Nwokedi EC, DiBiase SJ, Jabbour S, et al. Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme. Neurosurgery 2002; 50:41.
  26. Cardinale R, Won M, Choucair A, et al. A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. Int J Radiat Oncol Biol Phys 2006; 65:1422.
  27. Curran WJ Jr, Scott CB, Weinstein AS, et al. Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02. J Clin Oncol 1993; 11:857.
  28. Tsao MN, Mehta MP, Whelan TJ, et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. Int J Radiat Oncol Biol Phys 2005; 63:47.
  29. Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 2004; 60:853.
  30. Marin LA, Smith CE, Langston MY, et al. Response of glioblastoma cell lines to low dose rate irradiation. Int J Radiat Oncol Biol Phys 1991; 21:397.
  31. Sneed PK, Lamborn KR, Larson DA, et al. Demonstration of brachytherapy boost dose-response relationships in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1996; 35:37.
  32. Koot RW, Maarouf M, Hulshof MC, et al. Brachytherapy: Results of two different therapy strategies for patients with primary glioblastoma multiforme. Cancer 2000; 88:2796.
  33. Selker RG, Shapiro WR, Burger P, et al. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 2002; 51:343.
  34. Laperriere NJ, Leung PM, McKenzie S, et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys 1998; 41:1005.
  35. Wilson CB, Larson DA, Gutin PH. Radiosurgery: a new application? J Clin Oncol 1992; 10:1373.
  36. Cohen L, Awschalom M. Fast neutron radiation therapy. Annu Rev Biophys Bioeng 1982; 11:359.
  37. Cohen L, Hendrickson FR, Kurup PD, et al. Clinical evaluation of neutron beam therapy. Current results and prospects, 1983. Cancer 1985; 55:10.
  38. Griffin TW, Davis R, Laramore G, et al. Fast neutron radiation therapy for glioblastoma multiforme. Results of an RTOG study. Am J Clin Oncol 1983; 6:661.
  39. Castro JR, Saunders WM, Austin-Seymour MM, et al. A phase I-II trial of heavy charged particle irradiation of malignant glioma of the brain: a Northern California Oncology Group Study. Int J Radiat Oncol Biol Phys 1985; 11:1795.
  40. Castro JR, Phillips TL, Prados M, et al. Neon heavy charged particle radiotherapy of glioblastoma of the brain. Int J Radiat Oncol Biol Phys 1997; 38:257.
  41. Fitzek MM, Thornton AF, Rabinov JD, et al. Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a phase II prospective trial. J Neurosurg 1999; 91:251.
  42. Gerber DE, Grossman SA, Zeltzman M, et al. The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro Oncol 2007; 9:47.
  43. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8:1277.
  44. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28:1963.
  45. NCCN guidelines http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site.